Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20

Latest Articles in BioNTech

Pfizer Says Earliest US Filing For COVID-19 Vaccine Would Be Late November

Pfizer's shares were up 3.5% in afternoon trading, while BioNTech's U.S.-listed shares were up 3.9%. Moderna shares fell 1.5%.

Read More

New Zealand Signs Deal With Pfizer, Biontech For COVID-19 Vaccine

The Pfizer-BioNTech vaccine is one of the leading candidates in the race to be the first to get regulatory approval in the United States and Europe.

Read More

EU Reviewing Pfizer-Biontech COVID-19 Vaccine In Real Time

Pfizer and BioNTech said in a joint statement the start of the review is based on data from laboratory and animal testing, as well as early testing on humans

Read More

Pfizer Says Late-Stage Coronavirus Vaccine Study Shows Moderate Side Effects

The company has enrolled more than 29,000 people in its 44,000-volunteer trial to test the experimental COVID-19 vaccine it is developing with German partner BioNTech.

Read More

BioNTech Wins $445 Million German Grant For COVID-19 Vaccine

BioNTech and Pfizer are already testing their most promising vaccine candidate in late-stage trials and have started recruiting patients in the United States, Brazil, Argentina and Europe.

Read More

AstraZeneca Puts Leading COVID-19 Vaccine Trial On Hold Over Safety Concern

Shares of AstraZeneca fell more than 8% in after-hours U.S. trading, while shares of rival vaccine developers rose. Moderna Inc was up more than 4% and Pfizer Inc rose less than 1%.

Read More

Japan Says In Deal To Purchase Astrazeneca's COVID-10 Vaccine

The agreement comes after Japan announced a deal last week to buy 120 million doses of a COVID-19 vaccine candidate developed by Pfizer Inc and BioNTech SE.

Read More

Pfizer-BioNTech Begin Late-Stage Study Of Lead COVID-19 Vaccine Candidate

Patients are each given two doses of the drugmakers’ vaccine to help boost immunity, so the first 100 million doses would vaccinate around 50 million people.

Read More

US To Pay Pfizer, Biontech $1.95 Billion For 100 Million Doses Of Covid-19 Vaccine

According to the latest data from Johns Hopkins University, worldwide, the number of coronavirus cases has surged to 15,177,477 while the death toll has risen to 621,890.

Read More

US To Pay Pfizer, Biontech $1.95 Billion For COVID-19 Vaccine

Pfizer hopes to start its pivotal late-stage trial of the vaccine as early as next week, pending regulatory approvals, Chief Scientific Officer Mikael Dolsten said in an interview.

Read More

Britain Signs Deals With Pfizer, Biontech, Valneva For COVID-19 Vaccines

Britain also said on Monday it had secured treatments containing COVID-19-neutralising antibodies from AstraZeneca to protect people who can't be vaccinated.

Read More

BioNTech And Pfizer's COVID-19 Vaccine Shows Potential In Human Trial

The potential treatment is the fourth early-stage COVID-19 drug to show promise in human testing, along with projects involving Moderna, CanSino Biologics and Inovio Pharmaceuticals.

Read More

Temasek-Led Investor Group In $250 Million Vaccine Bet On Biontech

The investors are in for an early reckoning because BioNTech has said it expects first clinical data on its COVID-19 vaccine development programme known as BNT162 this month or in July.

Read More

Pfizer, BioNTech To Co-Develop Potential Coronavirus Vaccine

The drugmakers will start the collaboration immediately and have signed a letter of intent for the vaccine's distribution outside China, they said in a joint statement.

Read More